Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches
This model demonstrates that combining durable agents, extended dosing intervals and optimised delivery strategies (eg, prefilled syringes and DSF VF) can substantially improve the cost-effectiveness and sustainability of anti-VEGF therapy in public health systems.
Authors
- Francisco Jódar‐Sánchez (ORCID: https://orcid.org/0000-0003-1092-9932)
- Antonio Ruíz (ORCID: https://orcid.org/0000-0001-6423-6993)
- Saturnino Gismero-Moreno (ORCID: https://orcid.org/0000-0002-7632-6045)
- Francisco Rivas‐Ruiz (ORCID: https://orcid.org/0000-0002-8894-0501)
- Nuria García‐Agua Soler (ORCID: https://orcid.org/0000-0003-2979-5241)
Institutions
- Hospital Costa del Sol (ES)
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-103539
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00